NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 280)
Posted On: 05/31/2018 7:08:39 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Outlines Plans to Create Two Wholly Owned Subsidiaries
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced its intention to create two wholly owned subsidiaries to hold specific intellectual property. The first subsidiary will hold IP related to the improved processing and combustion-free delivery of nicotine and nicotine analogs, while the second subsidiary will hold IP related to the delivery of non-steroidal anti-inflammatory drugs, phosphodiesterase inhibitors and other active pharmaceutical ingredients. Per the update, this proposed structure, which is subject to ongoing legal and tax analysis, more suitably reflects the distinct customer bases and business applications for each subsidiary, allowing the company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. Notably, Lexaria expects that its patented DehydraTECH™ technology will be utilized by both subsidiaries.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced its intention to create two wholly owned subsidiaries to hold specific intellectual property. The first subsidiary will hold IP related to the improved processing and combustion-free delivery of nicotine and nicotine analogs, while the second subsidiary will hold IP related to the delivery of non-steroidal anti-inflammatory drugs, phosphodiesterase inhibitors and other active pharmaceutical ingredients. Per the update, this proposed structure, which is subject to ongoing legal and tax analysis, more suitably reflects the distinct customer bases and business applications for each subsidiary, allowing the company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. Notably, Lexaria expects that its patented DehydraTECH™ technology will be utilized by both subsidiaries.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)